Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma
Authors:
Open Access
- 1 March 2018
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1563-1570
Abstract
Background: Colorectal carcinoma (CRC) is one of the most common malignancies, and immunotherapy has opened a new field of cancer treatment in recent years. Generally, CRC does not benefit from immunotherapy. HHLA2, a member of the B7 family, is a novel immune checkpoint molecule, and the prognostic value of HHLA2 in CRC patients and the association between HHLA2 expression and clinicopathological characteristics remains unknown. Materials and methods: This study included 63 patients diagnosed with CRC, and their resected specimens were obtained and constructed as a tissue microarray. Expression of HHLA2 and CD8 was detected by the double immunohistochemistry method. Based on follow-up data, correlations of HHLA2 expression and clinicopathological features, including overall survival, in CRC patients were evaluated. Results: High HHLA2 expression was detected in CRC tumor tissues, compared to the adjacent noncancerous tissues. HHLA2 expression level was significantly related to the depth of invasion (P=0.044) and CD8+ T-cell infiltration status (P=0.016), and predicted high mortality rate (P=0.035). HHLA2 acted as an independent predictive factor in the overall survival of CRC patients (P=0.039, hazard ratio=2.162, 95% CI 1.041–3.084). Conclusion: HHLA2 expression is upregulated in CRC patients, and HHLA2 is an independent prognostic factor of overall survival of CRC patients. High HHLA2 expression is closely correlated with CD8 T-cell infiltration status and can predict poor prognosis in CRC patients.Keywords
This publication has 31 references indexed in Scilit:
- B7-H5 costimulates human T cells via CD28HNature Communications, 2013
- HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionProceedings of the National Academy of Sciences, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHCImmunogenetics, 2012
- Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung CancerJournal of Surgical Research, 2011
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- The B7 Family and Cancer Therapy: Costimulation and CoinhibitionClinical Cancer Research, 2007
- T-Cell Costimulation — Biology, Therapeutic Potential, and ChallengesNew England Journal of Medicine, 2006
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- Endogenous Retroviruses Provide the Primary Polyadenylation Signal for Two New Human Genes (HHLA2 and HHLA3)Genomics, 1999